# H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas

> **NCT02960230** · PHASE1,PHASE2 · COMPLETED · sponsor: **Sabine Mueller, MD, PhD** · enrollment: 50 (actual)

## Conditions studied

- Diffuse Intrinsic Pontine Glioma
- Glioma
- Diffuse Midline Glioma, H3 K27M-Mutant

## Interventions

- **BIOLOGICAL:** K27M peptide
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT02960230
- **Lead sponsor:** Sabine Mueller, MD, PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-18
- **Primary completion:** 2023-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2025-01-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02960230

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02960230, "H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas". Retrieved via AI Analytics 2026-09-05 from https://api.ai-analytics.org/clinical/NCT02960230. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*